SRR25043624
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.460
- ALLOGRAFT_REJECTION+0.450
- INTERFERON_GAMMA_RESPONSE+0.430
- COMPLEMENT+0.320
- INFLAMMATORY_RESPONSE+0.300
- KRAS_SIGNALING_UP+0.280
- MYOGENESIS+0.280
- CHOLESTEROL_HOMEOSTASIS+0.250
- HEME_METABOLISM+0.250
- IL6_JAK_STAT3_SIGNALING+0.240
Top 10 suppressed
- MYC_TARGETS_V2-0.520
- DNA_REPAIR-0.460
- OXIDATIVE_PHOSPHORYLATION-0.450
- MYC_TARGETS_V1-0.410
- E2F_TARGETS-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- WNT_BETA_CATENIN_SIGNALING-0.370
- ANGIOGENESIS-0.340
- G2M_CHECKPOINT-0.300
- ADIPOGENESIS-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-05-4410-01A-21R-1858-07 | — | cohortA1 | 0.831 |
| 2 | SRR23303769 | — | — | 0.821 |
| 3 | DRR168517 | — | — | 0.801 |
| 4 | TCGA-F7-A50G-01A-11R-A266-07 | — | — | 0.795 |
| 5 | 94b2af92-0cfc-40b2-977d-6bd0fa4440d9 | — | — | 0.785 |
| 6 | TCGA-CV-A45O-01A-21R-A24H-07 | — | — | 0.784 |
| 7 | 88340 | EPN | Supratentorial EPN | 0.778 |
| 8 | BS_FXJY0MNH | Diffuse intrinsic pontine glioma | — | 0.777 |
| 9 | SRR1430248 | GTEX | — | 0.777 |
| 10 | TCGA-CN-6013-01A-11R-1686-07 | — | — | 0.773 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.460 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.430 | Idelalisib | — uncovered |
| COMPLEMENT | 0.320 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.280 | Inavolisib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.250 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.250 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.240 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.220 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.180 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.170 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| COAGULATION | 0.130 | Binimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.050 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.040 | Inavolisib | — uncovered |